Up to 300 women will be recruited into the study (100 per group). This sample size will achieve 80% power to detect a reduction from 40% placental retention on the current regimen of non-pharmacological third stage management to 20% placental retention using either 5IU oxytocin IMI after delivery or 600 mcg misoprostol orally. Two pairwise comparisons between the current regimen and a new regimen will be conducted at 0.025 significance level each to attain an overall 0.05 significance level using a test of proportions. This sample size also allows for an interim analysis consisting of two pairwise tests, when 60 patients per group have been recruited (at the nominal significance level of 0.003 per test, critical Z-statistic=3.02) and a final analysis (at the nominal significance level of 0.024 per test, critical Z-statistic=2.25). Sequential sample size calculations were obtained using O'Brien-Fleming spending function for the test statistics boundaries (PASS 2002 for Windows, Kaysville Utah). At the time of interim analysis, the placental retention rate per study arm will be estimated and a possibility of stopping recruitment to one of the arms due to futility will be considered.